Access Expansion Greenbrook operates across the United States with a focus on accessible mental health care through non-invasive, evidence-based treatments like NeuroStar TMS Therapy and SPRAVATO. Sales opportunities exist in partnering with hospital systems, health plans, and clinics seeking to add FDA-cleared, FDA-cleared therapies to broaden patient access and treatment options.

Tech Enablement The company utilizes a modern tech stack including AWS, Salesforce, Snowplow, and marketing tools, indicating a data-driven, scalable operation. Potential upsell opportunities include integrating marketing automation, patient journey analytics, and CRM-driven outreach services for patient acquisition and retention.

Financial Momentum Recent financing activity with debt facilities and a prominent direct offering, plus a leadership change, signals active capital management and growth ambition. This suggests opportunity for financial services partnerships, ongoing capital advisory, and vendor financing arrangements to support clinic expansion.

Strategic Growth Appointment of new CFO and independent board member, coupled with delisting events and fundraising, points to strategic realignment and potential M&A or network expansion. Business development can target consolidation opportunities, co-management agreements, or partnerships to accelerate scale in psych mental health care.

Clinical Portfolio As a NeuroStar TMS and SPRAVATO provider with licensed clinicians and physician collaboration, Greenbrook prioritizes innovative, low-side-effect treatments. Cross-sell opportunities exist with manufacturers, payer partnerships, and clinic-grade technology vendors to optimize treatment delivery, compliance, and patient outcomes.